Immunotherapy for Tumor in the Brain: Insights From - and For - Other Tumor Sites
Lois A. Lampson
Immunotherapy for Tumor in the Brain: Insights From - and For - Other Tumor Sites - Frontiers Media SA 2018 - 1 electronic resource (95 p.)
Open Access
Tumor immunotherapy has now shown its promise for many, its disappointments and failings for others. Going forward, brain tumor patients can both benefit and contribute. Tumor immunotherapy is steadily progressing. As experience accumulates, it is important to consider its generality. The reviews herein emphasize the brain’s place among other tumor sites. Two major topics are addressed. THE SITE: WHAT CAN WE EXPECT FROM IMMUNOTHERAPY WHEN THE TARGET IS IN THE BRAIN? Experience with immunotherapy for different targets in the brain, including tumor and also pathogens, is reviewed. Long-standing assumptions are confronted. The potential for beneficial responses is stressed. BRAIN TUMOR IMMUNOTHERAPY: WHAT HAVE WE LEARNED SO FAR? Clinical experience with brain tumor immunotherapy, from a variety of centers, is reviewed. Primary tumors, emphasizing glioblastoma, and brain metastases are each considered.
Creative Commons
English
978-2-88945-535-5 9782889455355
10.3389/978-2-88945-535-5 doi
blood-brain barrier tumor antigen brain immunology glioblastoma brain tumor immunotherapy brain metastases brain tumor immune privilege
Immunotherapy for Tumor in the Brain: Insights From - and For - Other Tumor Sites - Frontiers Media SA 2018 - 1 electronic resource (95 p.)
Open Access
Tumor immunotherapy has now shown its promise for many, its disappointments and failings for others. Going forward, brain tumor patients can both benefit and contribute. Tumor immunotherapy is steadily progressing. As experience accumulates, it is important to consider its generality. The reviews herein emphasize the brain’s place among other tumor sites. Two major topics are addressed. THE SITE: WHAT CAN WE EXPECT FROM IMMUNOTHERAPY WHEN THE TARGET IS IN THE BRAIN? Experience with immunotherapy for different targets in the brain, including tumor and also pathogens, is reviewed. Long-standing assumptions are confronted. The potential for beneficial responses is stressed. BRAIN TUMOR IMMUNOTHERAPY: WHAT HAVE WE LEARNED SO FAR? Clinical experience with brain tumor immunotherapy, from a variety of centers, is reviewed. Primary tumors, emphasizing glioblastoma, and brain metastases are each considered.
Creative Commons
English
978-2-88945-535-5 9782889455355
10.3389/978-2-88945-535-5 doi
blood-brain barrier tumor antigen brain immunology glioblastoma brain tumor immunotherapy brain metastases brain tumor immune privilege